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ABSTRACT: Background. The impact of primary tumor volume (pTV) on
local control after definitive radiotherapy (RT) for head and neck squa-
mous cell carcinoma (HNSCC) is unclear.
Methods. Pertinent literature was reviewed to address the impact of pTV
on local control after definitive RT for HNSCC.
Results. Reproducibility of pTV calculations is probably influenced by
interobserver variability and may be reduced by relying on experi-
enced observers. The impact of pTV on local control after definitive
RT is probably influenced by primary site. A relatively limited impact
of pTV on local control after RT for oropharyngeal squamous cell
carcinomas (SCCs) might be attributable to human papillomavirus
(HPV) positivity.
Conclusion. pTV may be a useful parameter to select patients for treat-
ment with definitive RT, particularly for those with laryngeal SCCs. Patients
with high-volume primary cancers, in which the probability of local control
with a functional larynx is low, are likely better treated with surgery.
VC 2013 Wiley Periodicals, Inc. Head Neck 36: 1363–1367, 2014
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INTRODUCTION
The likelihood of local control after definitive radiother-
apy (RT) for head and neck squamous cell carcinoma
(HNSCC) depends on the radiosensitivity of the tumor
and extent of disease. Radiosensitivity varies with pri-
mary site as well as other factors, such as high-risk
human papillomavirus (HR-HPV) positivity and smoking
history.1,2 In general, squamous cell carcinomas (SCCs)
of the tonsillar fossa and base of tongue have a higher
likelihood of cervical lymph node metastases and are
more radiosensitive than oral cavity SCCs.3,4 To obtain
an acceptable local control rate for T1 to T2 oral tongue
SCCs treated with definitive RT, brachytherapy is used. It
is unclear if the dose escalation inherent in the inhomoge-
neity of brachytherapy, the more accurate delivery of the
radiation via implants compared to external radiation of a
potentially moving target, or the decreased overall treat-
ment time is the key to success. In order to obtain an
acceptable local control rate for T1 to T2 oral tongue
SCCs treated with definitive RT, it is necessary to com-
press the overall treatment time by using brachytherapy
to deliver most of the RT dose, whereas this is unneces-
sary for base of tongue SCCs.4,5 T1 to T2 anterior tonsil-
lar pillar SCCs have a 70% local control rate after
definitive RT, whereas T1 to T2 tonsillar fossa SCCs
have local control rates exceeding 90%.3
Primary tumor extent is stratified into a T-classification
based on parameters, such as maximum diameter, exten-
sion to adjacent sites, vocal cord fixation, and/or likeli-
hood of complete resectability. Tumor volume is another
parameter that reflects extent of disease and, depending
on the radiosensitivity of the tumor, may predict the like-
lihood of control after definitive RT.6–9 Primary tumor
volume (pTV) may vary significantly with primary site,
which may be related to the point at which symptoms are
produced and the diagnosis established. For series of
patients treated with a particular modality, such as RT,
the availability of other appropriate treatment options,
such as surgery for advanced laryngeal cancer, may influ-
ence the range of pTVs treated with RT.10,11 Patients
with high volume laryngeal cancers are more likely to
have cartilage destruction and a poor outcome after defin-
itive chemoradiotherapy (CRT) and are, thus, usually
treated with a total laryngectomy.12 It was not possible to
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accurately measure tumor volume before the availability
of computed tomography (CT) and magnetic resonance
imaging (MRI). However, over the last 2 decades, a num-
ber of authors have investigated the impact of pTV on
local control after definitive RT. Following is a review of
the pertinent literature.
Measuring primary tumor volume
In order to calculate pTV, the primary tumor is man-
ually delineated with a mouse on serial CT or MRI slices.
This allows the software to automatically calculate the
areas of the lesion and, from the thickness of the slice,
the volume of the tumor per slice and, finally, the sum of
the volumes of all the slices.13 The majority of the data
pertaining to the impact of pTV on outcome after defini-
tive RT have used diagnostic contrast-enhanced CT as
opposed to treatment planning CTs or MRIs. Some have
pointed out that MRIs are more accurate for measuring
tumor volume than using the CT images for tumors of the
oral cavity and oropharynx,14 if the contrast between the
tumor and the surrounding normal tissue is insufficient on
the CT images, if artifacts obscure the tumor on the CT
images, or if the tumor is very small.15
An issue central to the prognostic value of pTV is repro-
ducibility. Hermans et al16 reported on a study evaluating
intraobserver and interobserver variability using pretreat-
ment CT to calculate pTV for 13 patients with laryngeal
tumors. Five observers calculated the pTV in 4 different
sessions. Significant variability was detected and was
related to both observer (p < .0001) and session (p < .01).
Interobserver variability was the most important compo-
nent and accounted for 89.3% of total variability. The
authors stated that it would be ideal for one experienced
observer to calculate pTVs. In agreement with these data,
Gordon et al,17 using an interactive computer program that
enabled the extraction of tumor volumes from 3D MRI
data in patients with pharyngeal carcinoma, determined the
measurement error and percentage measurement error
(intraobserver variability). The mean and median percent-
age measurement errors, respectively, were 13% and 12%
for primary tumors, which had no statistical significance.
In contrast, Mukherji et al18 reported excellent interob-
server reproducibility for 4 neuroradiologists and 4 expe-
rienced radiation oncologists from different institutions
who were asked to calculate the pTV on pretreatment
CTs for 20 patients with supraglottic carcinomas. Been et
al19 reported on 70 patients with oropharyngeal SCCs in
which the pTVs were calculated on pretreatment CTs by
2 observers and found high interobserver correlation.
It is likely that there is a variable degree of reproduci-
bility when calculating pTVs and that this is mostly
because of interobserver variability. Reproducibility is
likely improved by using a small number of experienced
observers and limiting pTV determinations to 1 type of
imaging, such as pretreatment diagnostic CT, as opposed
to MRI or treatment planning CT. Parenthetically, the
author’s impression is that treatment planning CTs tend
to overestimate pTVs compared with diagnostic CTs.
In an attempt to improve accuracy of primary tumor
delineation, 18F-fluorodeoxyglucose (18FDG) positron
emission tomography (PET) has been incorporated in radi-
ation treatment planning process. 18FDG-PET-defined
pTVs were consistently found to be significantly smaller
compared with those based on pretreatment CT or MRI
scans, but may offer the best approximation of the pTV as
defined in the surgical specimen.20,21 Although the PET-
defined volume is highly dependent on the method of the
PET signal segmentation tool,22 fusion of PET and CT
information can improve intraobserver and interobserver
variability.23,24 A drawback of PET is that it is not anatom-
ically as accurate as CT or MRI to precisely define pTV.
Impact of primary tumor volume on local control
A number of authors have reported on the impact of
tumor volume on outcome after definitive RT alone or
combined with adjuvant chemotherapy with variable
results.10,12,13,19,25–39 In general, most authors have found
that, depending on primary site, prognosis is inversely
related to tumor volume.25,26,30,31,34 Knegjens et al28
reported on 360 patients treated with definitive CRT for
locoregionally advanced SCCs of the oral cavity (22.4%),
oropharynx (62.3%), and hypopharynx (15.2%) and fol-
lowed for a median of 19.8 months. PTV was calculated
on pretreatment CT or MRI; the median pTV was 28.7 cc
(range, 2.1–187.7 cc). Multivariate analysis revealed a
significant impact of pTV on local control. The authors
observed that the hazard ratio for a local recurrence
increased 14% for every 10 cc increase in pTV.
Mendenhall et al6 reported on 404 patients treated with
definitive RT alone (358 patients) or combined with
adjuvant chemotherapy (46 patients) at the University of
Florida and followed for a median of 3.5 years (range,
0.25–20.25 years). All living patients had a minimum 2-
year follow-up. Pretreatment pTV was calculated on diag-
nostic CT. The number of patients with tumors in the vari-
ous primary sites and the T classification distribution is
depicted in Table 1. Forty-two of 45 patients with
hypopharyngeal SCCs had primary lesions arising in the
pyriform sinus. SCCs arising in the anterior tonsillar pillar
were observed in 37 patients and in the soft palate in 12
patients. The 5-year local control rates were: tonsillar
fossa/posterior tonsillar pillar, 86%; base of tongue, 84%;
anterior tonsillar pillar/soft palate, 74%; supraglottis, 76%;
glottis, 68%; and hypopharynx, 85%. Multivariate analysis
of local control for the overall population revealed that the
only parameter significantly related to this endpoint was T
classification. Multivariate analysis stratified by primary
site revealed that pTV significantly influenced local con-
trol for patients with SCCs of the supraglottis (p5 .0220)
and glottis (p5 .0042) but not for those with SCCs of the
tonsillar fossa/posterior tonsillar pillar (p5 .0892), base of
tongue (p5 .9493), anterior tonsillar pillar/soft palate (p 5
.5909), and hypopharynx (p5 .2282). A caveat is that the
HR-HPV status of the tumors was not determined in this
study. Because HR-HPV–related tumors are often smaller
and more radiosensitive and chemosensitive compared
with HR-HPV–negative tumors, it is possible that HR-
HPV positivity masked the prognostic strength of pTV in
oropharyngeal SCCs.40
Impact of primary site and primary tumor volume on
local control
Nasopharynx. Sze et al32 reported on 308 patients treated
with definitive RT at the Pamela Youde Nethersole
MENDENHALL ET AL.
1364 HEAD & NECK—DOI 10.1002/HED SEPTEMBER 2014
Eastern Hospital (Hong Kong) between 1998 and 2001.
Pretreatment MRIs were used to calculate the pTV,
including retropharyngeal node metastases. Patients
received 70 Gy at 2 Gy per fraction; 128 patients (42%)
received adjuvant chemotherapy. Median pTV was 22 cc
(range, 1.4–218 cc). Median pTVs stratified by T classifi-
cation were: T1, 2.7 cc; T2, 13.2 cc; T3, 28.1 cc; and T4,
65.5 cc. Median follow-up was 1.9 years (range, 0.1–3.9
years). The 3-year local control rates were 97% for
patients with pTVs <15 cc and 87% for those with pTVs
15 cc (p < .01). Multivariate analysis revealed that pTV
significantly impacted local control (p < .01). The authors
estimated that the risk of a local recurrence increased
approximately 1% for every 1 cc increase in pTV.
Chua et al33 reported on 116 patients treated at the
Queen Mary Hospital (University of Hong Kong) with
definitive RT alone for T1 (67 patients) and T2 (49
patients) nasopharyngeal carcinomas between 1989 and
1991. Sixty-eight patients had a clinically negative neck
(cN0); the remainder had N1 neck disease. Pretreatment
CTs were used to calculate the pTVs. The median pTVs
were: T1, 7.6 cc (range, 1.3–29.1 cc); and T2, 22.7 cc
(range, 5.7–75.5 cc). The 5-year local control rates were:
pTV 15 cc, 93%; and pTV >15 cc, 82% (p5 .033).
Oropharynx
Chao et al41 reported on 79 patients with SCC of the oro-
pharynx, treated with definitive or postoperative intensity-
modulated radiation therapy (IMRT; 17 of them also
received platinum-based chemotherapy), between 1997
and 2001 at the MD Anderson Cancer Center. Thirty-one
definitive IMRT patients were included in the volumetric
study. On multivariate analysis, pTV and nodal volume
were recognized as independent factors determining
locoregional control and disease-free survival.
Been et al19 reported on 79 patients with oropharyngeal
SCC treated with definitive RT at the University of Wis-
consin between 1991 and 2005. PTVs were calculated on
pretreatment CTs by 2 observers. The mean pTV was
13.13 cc (range, 0.27–77.76 cc). Follow-up ranged from
4.9 to 165.8 months (median, 30.1 months). PTV did not
correlate significantly with locoregional control. Locore-
gional control was significantly lower for patients with
T4 cancers compared with those with T1 to T3 SCCs.
Hermans et al36 reported on 112 patients with tonsillar
SCCs treated with definitive RT and followed for
33 months. PTVs were calculated on pretreatment CTs.
PTV was found to significantly predict local control when
stratified by quartiles (p < .05) but not within T2 to T4
cancers. Multivariate analysis revealed that T classifica-
tion significantly impacted local control (p5 .02),
whereas pTV did not significantly impact this endpoint.
Nathu et al39 reported on 114 patients with T2 to T4
oropharyngeal SCCs treated at the University of Florida
between 1983 and 1995 with definitive RT alone (102
patients) or preceded by 2 to 3 cycles of induction chem-
otherapy (12 patients). PTVs were calculated on pretreat-
ment diagnostic CT scans. All survivors had a minimum
2-year follow-up. Multivariate analysis revealed that T
classification significantly impacted local control
(p5 .02), whereas pTV did not significantly influence
this endpoint (p5 .10).
Lok et al42 reported on 340 patients with oropharyngeal
SCC, treated with IMRT in combination with platinum-
based chemotherapy in the majority of them, between
1998 and 2009 at the Memorial Sloan–Kettering Center.
The pTV was calculated using original RT plans in which
the gross tumor volumes were contoured based on all
available imaging and clinical examination. Large-size
pTV (>32.79 cm3) and advanced T classification tumors
were found significantly associated with local failure
when using univariate competing risks regression models;
multivariate analysis was not performed because of the
low number of local failure events. Furthermore, pTV
was identified as an independent risk factor (together
with N classification) for distant control and overall
survival.
Supraglottis
Kraas et al35 reported on 28 patients treated with defin-
itive RT for supraglottic SCC at Wake Forest University
between 1991 and 1997. PTVs were calculated on pre-
treatment CTs. Follow-up ranged from 20 to 58 months.
pTVs ranged from 0 to 68.6 cc with a median of 3.1 cc.
The 2-year local control rates were: pTV <8 cc, 70%;
pTV >8 cc, 20%; and overall, 61% (p5 .0077).
Hermans et al37 reported on 103 patients treated with
definitive RT for supraglottic SCC and followed for an
average of 3.4 years. PTVs were determined based on
pretreatment CTs. Multivariate analysis revealed that pre-
epiglottic space invasion (p< .01) and subglottic exten-
sion (p< .01) significantly influenced local control.
Although pTVs significantly impacted local control in the
TABLE 1. Primary site, primary tumor volume, and T classification distribution for 404 patients treated at the University of Florida.
TF/PTP BOT ATP/SP SGL Glottis HPX
No. of patients 69 72 49 114 55 45
T classification
T1 3 3 1 4 0 6
T2 27 28 25 47 4 33
T3 25 23 16 51 47 4
T4 14 17 7 12 4 2
Median pTV, cc 9.2 14.8 5.2 5.4 2.9 3.9
pTV range, cc 0–187.5 1.5–235 0–99.9 0–65.8 0.8–8.2 0–.35.4
Abbreviations: TF-PTP, tonsillar fossa-posterior tonsillar pillar; BOT, base of tongue; ATP/SP, anterior tonsillar pillar/soft palate; SGL, supraglottis; HPX, hypopharynx; pTV, planning tumor volume.
This table was republished with permission from Mendenhall et al.,6 Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck. Head
Neck 2003;25:535–542.VC Wiley 2003.
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univariate analysis (p5 .0023), it was not found to be sig-
nificant in the multivariate analysis (p5 .3288).
Mancuso et al13 reported on 63 patients treated with
definitive RT for supraglottic SCC at the University of
Florida between 1982 and 1991. The T classification dis-
tribution was as follows: T1, 1 patient; T2, 23 patients;
T3, 37 patients; and T4, 2 patients. PTVs were calculated
on pretreatment diagnostic CTs. Patients were followed
for a minimum of 2 years or until local recurrence. Local
control versus pTV revealed: < 6 cc, 34 of 38 patients
(89%); and 6 cc, 13 of 25 patients (52%; p5 .0012).
The overall local control rate was 47 of 63 patients
(75%). Local control with preservation of laryngeal func-
tion was obtained in 44 of 63 patients (70%). Local con-
trol with preservation of a functional larynx versus pTV
was obtained in 34 of 38 patients (89%) with pTVs <6
cc compared with 10 of 25 patients (40%) with pTVs 6
cc (p5 .00004). Multivariate analysis of local control
(p5 .0005) and local control with a functional larynx
(p5 .0001) revealed that both of these endpoints were
independently impacted by pTV, whereas neither were
significantly influenced by T classification, N classifica-
tion, preepiglottic space invasion, sex, or cord mobility.
Glottis
Pameijer et al43 reported on 42 patients with T3 fixed
cord glottic SCCs who were treated with definitive RT at
the University of Florida between 1980 and 1993. PTV
was calculated on pretreatment diagnostic CTs. Patients
were followed for a minimum of 2 years or until local
recurrence. Median follow up was 51 months (range, 4
months to 14 years). Local control after RT was observed
in 30 of 42 patients (71%). Four patients underwent a
total laryngectomy for a suspected local recurrence versus
necrosis and had no pathologic evidence of persistent
SCC so that 26 of 46 patients (62%) had local control
with laryngeal preservation. Local control with laryngeal
preservation was observed in 22 of 26 patients (85%)
with pTVs 3.5 cc compared with 4 of 16 patients (25%)
with pTVs >3.5 cc (p5 .0002).
Pyriform sinus
Pameijer et al38 reported on 23 patients with T1 (5
patients) or T2 (18 patients) SCCs of the pyriform sinus
treated with definitive RT at the University of Florida
between 1984 and 1993. PTVs were calculated on pre-
treatment diagnostic CTs. Patients were followed for a
minimum of 2 years or until local recurrence. Local con-
trol was observed in 18 of 23 patients (78%): 17 of 19
patients (89%) with pTVs 6.5 cc compared with 1 of 4
patients with pTVs >6.5 cc (p5 .021). Bulk disease at the
apex (10 mm) was also associated with a decreased
probability of local control (p5 .027). However, an update
of the University of Florida data with 45 patients (42 of
45 patients had pyriform sinus primary sites) revealed no
significant impact of pTV on local control (p5 .2282)
after definitive RT for hypopharyngeal SCCs.6
Further developments
In recent years, some refinements have been proposed
in order to more accurately predict the outcome of
patients after definitive RT based on pTV. In general,
they are preliminary studies that need further validation.
Metabolically active tumor volume has been measured
on pretreatment PET scans in patients treated by CRT. Seol
et al44 reported a relationship between 18FDG-PET maxi-
mum standardized uptake value and the metabolic tumor
volume with the progression-free survival and overall sur-
vival. A higher metabolic tumor volume of 9.3 cm was sig-
nificantly associated with an increased risk of recurrence
(2.19-fold; p5 .006) and death (1.62-fold; p5 .051).
Based on the relative radioresistance of hypoxic tumor
cells to RT, the prognostic impact of the hypoxic tumor
volume has been studied by Dunst et al.45 The total tumor
volume was calculated on pretreatment CT scans, and, in
addition, all patients underwent measurement of tumor
oxygenation by pO2 histography. The hypoxic tumor vol-
ume was defined as the product of the total tumor volume
and the relative frequency of pO2 readings <5 mm Hg.
Total tumor volume had a significant impact on survival,
and the hypoxic tumor volume was also significantly dif-
ferent in patients who had died compared to surviving
patients (11 vs 22 cm3; p5 .009), whereas the nonhypoxic
tumor volume was not prognostically significant. Although
the total tumor volume is a major prognostic factor, its
impact may be dependent on hypoxic tumor volume.
CONCLUSIONS
The reproducibility of pTV calculations likely is influ-
enced by the imaging modality and the experience and
number of observers. The preferred imaging modality is
probably contrast-enhanced diagnostic pretreatment CT
using a minimum number of experienced observers.
The impact of pTV on local control varies with the pri-
mary site and is likely related to the radioresistance of
the SCCs. Size for size, glottic and, to a lesser extent,
supraglottic SCCs are probably more radioresistant than
oropharyngeal SCCs and, thus, local control after RT is
influenced to a greater degree by pTV for the former
compared with the latter. Other parameters, such as HR-
HPV and smoking status, also impact the likelihood of
local control after RT for patients with oropharyngeal
SCCs, which may mitigate the impact of pTV for at least
those who are HR-HPV positive. The N classification
likely impacts the probability of regional control, and,
thus, locoregional control, but probably has little impact
on local control.
Finally, the threshold at which local control decreases
with increasing pTV probably varies from one institution
to the next depending on how pTVs are calculated and
would best be determined based on pTV outcome data
from the institution in question. This would be most use-
ful for patients with glottic and supraglottic SCCs and
possibly, to a lesser extent, pyriform sinus cancers.
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